tysabri
biogen netherlands b.v. - natalizumabas - išsėtinė sklerozė - selektyvūs imunosupresantai - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
magne b6
opella healthcare france sas - magnio laktatas dihidratas/piridoksino hidrochloridas - dengtos tabletės - 470 mg/5 mg - magnesium (different salts in combination)
magne b6
sia scandic pharma - magnio laktatas dihidratas/piridoksinas - dengtos tabletės - 470 mg/5 mg - magnesium (different salts in combination)
magne b6
tojaris projektai, uab - magnio laktatas dihidratas/piridoksinas - dengtos tabletės - 470 mg/5 mg - magnesium (different salts in combination)
magne b6
lex ano, uab - magnio laktatas dihidratas/piridoksinas - dengtos tabletės - 470 mg/5 mg - magnesium (different salts in combination)
magnerot
wörwag pharma gmbh & co. kg - magnio orotato dihidratas - tabletės - 500 mg - magnesium orotate
magnio sulfatas sanitas
pharmaswiss Česká republika s.r.o. - magnio sulfatas heptahidratas - injekcinis tirpalas - 250 mg/ml - magnesium sulfate
magvit
richard bittner ag - magnio laktatas dihidratas/piridoksinas - skrandyje neirios dengtos tabletės - 470 mg/5 mg - magnesium lactate
magvit b6
lex ano, uab - magnio laktatas dihidratas/piridoksinas - dengtos tabletės - 470 mg/5 mg - magnesium lactate
magvit b6
nemuno vaistinė, uab - magnio laktatas dihidratas/piridoksinas - dengtos tabletės - 470 mg/5 mg - magnesium lactate